10-Q: Serina Therapeutics Reports Second Quarter 2024 Results Following Merger, Cites Going Concern Uncertainty

Serina Therapeutics reports its second quarter 2024 results, which include the impact of a recent merger and highlight ongoing financial challenges.

Summary

• Serina Therapeutics, formerly AgeX Therapeutics, completed a merger with Legacy Serina on March 26, 2024, with Legacy Serina being the accounting acquirer.
• The company's Q2 2024 results reflect the combined entity's performance from March 27 to June 30, 2024, and Legacy Serina's standalone results prior to the merger.
• For the six months ended June 30, 2024, Serina reported a net loss of $9.8 million and used $9.6 million in net cash from operating activities.
• The company's cash and cash equivalents stood at $6.1 million as of June 30, 2024, and management believes this, along with expected proceeds from Juvenescence, will not be sufficient to fund operations for the next twelve months.
• There is substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
• The company is a clinical-stage biotechnology company focused on developing drug product candidates for neurological diseases and pain using its POZ drug delivery technology.
• The merger was treated as a reverse recapitalization, with Legacy Serina considered the accounting acquirer.
• The company's common stock began trading on the NYSE American under the symbol SER following the merger.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a going concern warning and material weaknesses in internal controls, which overshadow the potential of the company's technology and recent merger. The sentiment is negative due to the financial instability and operational risks.

Positives

• The company completed a merger with Legacy Serina, which is expected to provide a platform for future growth.
• The company received $4.9 million from Juvenescence through the exercise of Post-Merger Warrants.
• The company expects to receive an additional $10 million from Juvenescence through the exercise of remaining Post-Merger Warrants.
• The company has a proprietary POZ technology that could improve drug delivery.

Negatives

• The company reported a net loss of $9.8 million for the six months ended June 30, 2024.
• The company used $9.6 million in net cash from operating activities for the six months ended June 30, 2024.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's disclosure controls and procedures were deemed ineffective due to material weaknesses.
• The company has a significant amount of debt to Juvenescence.

Risks

• The company's ability to raise sufficient additional capital to finance its operations is uncertain.
• The company is subject to risks and uncertainties common to early-stage biotechnology companies.
• The company's therapeutic drug candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval.
• The company may not be able to obtain regulatory approval for its product candidates.
• The company's financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classifications of liabilities that might be necessary should the company be unable to continue as a going concern.
• The company has material weaknesses in its internal controls over financial reporting.

Future Outlook

The company expects to incur substantial expenditures in the foreseeable future for the development of its product candidates and will require additional financing to continue this development. Management believes that its cash and cash equivalents of $6.1 million as of June 30, 2024, along with the approximately $10 million of cash proceeds expected to be received from Juvenescence through the exercise of Juvenescence's remaining Post-Merger Warrants, will be used to fund company operations but are not expected to be sufficient to satisfy the company's anticipated operating and other funding requirements for the twelve months from the issuance of these condensed consolidated interim financial statements.

Management Comments

• Management believes that its cash and cash equivalents of $6.1 million as of June 30, 2024, along with the approximately $10 million of cash proceeds expected to be received from Juvenescence through the exercise of Juvenescence's remaining Post-Merger Warrants, will be used to fund company operations but are not expected to be sufficient to satisfy the company's anticipated operating and other funding requirements for the twelve months from the issuance of these condensed consolidated interim financial statements.
• Management has based its estimate of the funds needed to finance Company operations on assumptions that may prove to be wrong, and available capital resources could be exhausted sooner than expected.

Industry Context

The company operates in the biotechnology industry, which is characterized by high research and development costs, long development timelines, and regulatory uncertainty. The company's focus on neurological diseases and pain aligns with areas of significant unmet medical need. The company's POZ technology is a novel approach to drug delivery that could provide a competitive advantage.

Comparison to Industry Standards

• The company's financial results are not directly comparable to established pharmaceutical companies due to its early stage of development.
• The company's cash burn rate is high, which is typical for clinical-stage biotechnology companies.
• The company's reliance on external funding is also typical for companies in this sector.
• The company's focus on a novel drug delivery technology is similar to other companies seeking to improve drug efficacy and safety.
• The company's going concern warning is not uncommon for early-stage biotech companies that have not yet generated revenue.

Legal Proceedings

• A purported stockholder of AgeX filed a putative shareholder class action and derivative lawsuit in the Superior Court of the State of California, County of Alameda, captioned Buttner, et al. v. AgeX Therapeutics, Inc., et al., Case No. 23CV057083. The plaintiff released and discharged the defendants from all causes of action related to the Buttner Complaint pursuant to the terms of a settlement agreement entered into on May 8, 2024.

Related Party Transactions

• The company has significant related party transactions with Juvenescence, including loans, warrants, and indemnification agreements.
• AgeX transferred assets to UniverXome, which assumed AgeX's debt to Juvenescence.
• Juvenescence agreed to exercise all Post-Merger Warrants it holds to provide the company with an additional $15 million in capital.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern uncertainty and need for additional capital.
• Employees may be impacted by potential cost-cutting measures or restructuring if the company is unable to secure additional funding.
• Customers and partners may be concerned about the company's ability to continue operations and fulfill its obligations.
• Creditors, particularly Juvenescence, have a significant stake in the company's financial stability.

Next Steps

• The company intends to use the proceeds from the exercise of Post-Merger Warrants for general corporate purposes.
• The company anticipates submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration with plans to initiate a Phase 1 clinical trial in advanced Parkinson's disease patients in 2025.
• The company will continue to monitor and evaluate the effectiveness of its internal controls and procedures over financial reporting on an ongoing basis and are committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.

Key Dates

Keywords

Serina Therapeutics, Merger, Biotechnology, POZ technology, Neurological diseases, Drug delivery, Clinical-stage, Going concern, Warrants, Juvenescence, Financial results, Reverse recapitalization